A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis

Journal of Autoimmunity

Volumn 52, Issue , 2014, Pages 139-145

  Zisimopoulou, P ^a   Evangelakou, P ^a,b   Tzartos, J ^a   Lazaridis, K ^a   Zouvelou, V ^c   Mantegazza, R ^d   Antozzi, C ^d   Andreetta, F ^d   Evoli, A ^e   Deymeer, F ^f   Saruhan Direskeneli, G ^f   Durmus, H ^f   Brenner, T ^g   Vaknin, A ^g   Berrih Aknin, S ^h   Frenkian Cuvelier, M ^h   Stojkovic, T ^h   DeBaets, M ⁱ   Losen, M ⁱ   Martinez Martinez, P ⁱ   Kleopa, K A ^j   Zamba Papanicolaou, E ^j   Kyriakides, T ^j   Kostera Pruszczyk, A ^k   Szczudlik, P ^k   Szyluk, B ^k   Lavrnic, D ^l   Basta, I ^l   Peric, S ^l   Tallaksen, C ^m   Maniaol, A ^m   Tzartos, S J ^a,b   more..

^a HELLENIC PASTEUR INSTITUTE   (Greece)

^b UNIVERSITY OF PATRAS   (Greece)

^c NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^d DEPARTMENT OF NEUROSURGERY   (Italy)

^e CATHOLIC UNIVERSITY   (Italy)

^f ISTANBUL UNIVERSITY   (Turkey)

^g HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^h SORBONNE UNIVERSITÉ   (France)

ⁱ MAASTRICHT UNIVERSITY   (Netherlands)

^j CYPRUS INSTITUTE OF NEUROLOGY AND GENETICS   (Cyprus)

^k MEDICAL UNIVERSITY OF WARSAW   (Poland)

^l CLINICAL CENTER OF SERBIA   (Serbia)

^m ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

more..

Author keywords

Autoantibodies; Cell based assay; Diagnosis; LRP4; Myasthenia gravis; Therapy

Indexed keywords

ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G4; LIPOPROTEIN RECEPTOR RELATED PROTEIN 4 ANTIBODY; PREDNISONE; PYRIDOSTIGMINE; UNCLASSIFIED DRUG; CHOLINERGIC RECEPTOR; MUSK ANTIBODY; PROTEIN ANTIBODY; AUTOANTIBODY; IMMUNOGLOBULIN G; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; LRP4 PROTEIN, HUMAN; MUSK PROTEIN, HUMAN; PROTEIN TYROSINE KINASE;

ADULT; ARTICLE; CELL ASSAY; CLINICAL FEATURE; CLINICAL STUDY; CONTROLLED STUDY; CYPRUS; DISEASE SEVERITY; FEMALE; FRANCE; GREECE; HEK293 CELL LINE; HUMAN; HUMAN CELL; HYPERPLASIA; IMMUNOSUPPRESSIVE TREATMENT; ISRAEL; ITALY; MAJOR CLINICAL STUDY; MALE; MYASTHENIA GRAVIS; NETHERLANDS; NORWAY; POLAND; POPULATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SERBIA; TREATMENT RESPONSE; ASSAY; CELL BASED ASSAY; MULTICENTER STUDY; SERUM; THYMOMA; ADOLESCENT; AGED; BLOOD; CHILD; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE COURSE; IMMUNOLOGY; INFANT; INTERNATIONAL COOPERATION; MIDDLE AGED; NEWBORN; ONSET AGE; PATHOLOGY; PRESCHOOL CHILD; PROCEDURES; SEROLOGY; SEX DIFFERENCE; THYMUS; YOUNG ADULT;

ADOLESCENT; ADULT; AGE OF ONSET; AGED; AUTOANTIBODIES; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; FEMALE; HEK293 CELLS; HUMANS; HYPERPLASIA; IMMUNOGLOBULIN G; INFANT; INFANT, NEWBORN; INTERNATIONAL COOPERATION; LDL-RECEPTOR RELATED PROTEINS; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, CHOLINERGIC; SEROLOGIC TESTS; SEX FACTORS; THYMUS GLAND; YOUNG ADULT;

EID: 84904307500     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2013.12.004     Document Type: Article

References (33)

1. Marques M.J., Conchello J.A., Lichtman J.W. From plaque to pretzel: fold formation and acetylcholine receptor loss at the developing neuromuscular junction. JNeurosci 2000, 20:3663-3675.
2. Weatherbee S.D., Anderson K.V., Niswander L.A. LDL-receptor-related protein 4 is crucial for formation of the neuromuscular junction. Development 2006, 133:4993-5000.
3. Meriggioli M.N., Sanders D.B. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 2009, 8:475-490.
4. Lefvert A.K., Cuenoud S., Fulpius B.W. Binding properties and subclass distribution of anti-acetylcholine receptor antibodies in myasthenia gravis. JNeuroimmunol 1981, 1:125-135.
5. Rodgaard A., Nielsen F.C., Djurup R., Somnier F., Gammeltoft S. Acetylcholine receptor antibody in myasthenia gravis: predominance of IgG subclasses 1 and 3. Clin Exp Immunol 1987, 67:82-88.
6. Vincent A., Drachman D.B. Myasthenia gravis. Adv Neurol 2002, 88:159-188.
7. Hoch W., McConville J., Helms S., Newsom-Davis J., Melms A., Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001, 7:365-368.
8. McConville J., Farrugia M.E., Beeson D., Kishore U., Metcalfe R., Newsom-Davis J., et al. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol 2004, 55:580-584.
9. Boneva N., Frenkian-Cuvelier M., Bidault J., Brenner T., Berrih-Aknin S. Major pathogenic effects of anti-MuSK antibodies in myasthenia gravis. JNeuroimmunol 2006, 177:119-131.
10. Niks E.H., van Leeuwen Y., Leite M.I., Dekker F.W., Wintzen A.R., Wirtz P.W., et al. Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1. JNeuroimmunol 2008, 195:151-156.
11. Leite M.I., Jacob S., Viegas S., Cossins J., Clover L., Morgan B.P., et al. IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis. Brain 2008, 131:1940-1952.
12. Higuchi O., Hamuro J., Motomura M., Yamanashi Y. Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol 2011, 69:418-422.
13. Zhang B., Tzartos J.S., Belimezi M., Ragheb S., Bealmear B., Lewis R.A., et al. Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch Neurol 2012, 69:445-451.
14. Pevzner A., Schoser B., Peters K., Cosma N.C., Karakatsani A., Schalke B., et al. Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis. JNeurol 2012, 259:427-435.
15. Zouvelou V., Zisimopoulou P., Rentzos M., Karandreas N., Evangelakou P., Stamboulis E., et al. Double seronegative myasthenia gravis with anti-LRP 4 antibodies. Neuromuscul Disord 2013, 23:568-570.
16. Jaretzki A., Barohn R.J., Ernstoff R.M., Kaminski H.J., Keesey J.C., Penn A.S., et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 2000, 55:16-23.
17. Vincent A., Leite M.I., Farrugia M.E., Jacob S., Viegas S., Shiraishi H., et al. Myasthenia gravis seronegative for acetylcholine receptor antibodies. Ann N Y Acad Sci 2008, 1132:84-92.
18. Cossins J., Belaya K., Zoltowska K., Koneczny I., Maxwell S., Jacobson L., et al. The search for new antigenic targets in myasthenia gravis. Ann N Y Acad Sci 2012, 1275:123-128.
19. Meriggioli M.N., Sanders D.B. Muscle autoantibodies in myasthenia gravis: beyond diagnosis?. Expert Rev Clin Immunol 2012, 8:427-438.
20. Yang L., Maxwell S., Leite M.I., Waters P., Clover L., Fan X., et al. Non-radioactive serological diagnosis of myasthenia gravis and clinical features of patients from Tianjin, China. JNeurol Sci 2011, 301:71-76.
21. Zouvelou V., Kyriazi S., Rentzos M., Belimezi M., Micheli M.A., Tzartos S.J., et al. Double-seropositive myasthenia gravis. Muscle Nerve 2013, 47:465-466.
22. Poulas K., Koutsouraki E., Kordas G., Kokla A., Tzartos S.J. Anti-MuSK- and anti-AChR-positive myasthenia gravis induced by d-penicillamine. JNeuroimmunol 2012, 250:94-98.
23. Poulas K., Tsibri E., Kokla A., Papanastasiou D., Tsouloufis T., Marinou M., et al. Epidemiology of seropositive myasthenia gravis in Greece. JNeurol Neurosurg Psychiatr 2001, 71:352-356.
24. Guptill J.T., Sanders D.B., Evoli A. Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Muscle Nerve 2011, 44:36-40.
25. Evoli A., Tonali P.A., Padua L., Monaco M.L., Scuderi F., Batocchi A.P., et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 2003, 126:2304-2311.
26. Verschuuren J.J., Huijbers M.G., Plomp J.J., Niks E.H., Molenaar P.C., Martinez-Martinez P., et al. Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4. Autoimmun Rev 2013, 12:918-923.
27. Tuzun E., Christadoss P. Complement associated pathogenic mechanisms in myasthenia gravis. Autoimmun Rev 2013, 12:904-911.
28. Evoli A., Bianchi M.R., Riso R., Minicuci G.M., Batocchi A.P., Servidei S., et al. Response to therapy in myasthenia gravis with anti-MuSK antibodies. Ann N Y Acad Sci 2008, 1132:76-83.
29. Oh S.J. Muscle-specific receptor tyrosine kinase antibody positive myasthenia gravis current status. JClin Neurol 2009, 5:53-64.
30. Evoli A., Padua L. Diagnosis and therapy of myasthenia gravis with antibodies to muscle-specific kinase. Autoimmun Rev 2013, 12:931-935.
31. Marx A., Pfister F., Schalke B., Saruhan-Direskeneli G., Melms A., Strobel P. The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes. Autoimmun Rev 2013, 12:875-884.
32. Lauriola L., Ranelletti F., Maggiano N., Guerriero M., Punzi C., Marsili F., et al. Thymus changes in anti-MuSK-positive and -negative myasthenia gravis. Neurology 2005, 64:536-538.
33. Leite M.I., Strobel P., Jones M., Micklem K., Moritz R., Gold R., et al. Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG. Ann Neurol 2005, 57:444-448.